Gastrointestinal Cancer | Specialty

Eng Expands on Evolving GI Cancer Landscape

August 9th 2018

Cathy Eng, MD, highlights recent data that could shape the treatment landscape for several gastrointestinal cancers.

Dr. Shah Discusses the BRIGHTER Study in Gastric Cancer

August 9th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

August 9th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Shah Shares Immunotherapy, STAT3 Inhibitor Data in GI Cancers

August 8th 2018

Manish A. Shah, MD, shares insight on the challenges that remain in the treatment of esophageal and gastric cancers.

Dr. Finn Discusses Sequencing Therapy for HCC

August 7th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC

August 7th 2018

The FDA has granted a breakthrough therapy designation to the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr. Bekaii-Saab Reflects on the Findings of the ReDOS Trial in mCRC

August 7th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.

Expert Details Latest Data Across GI Cancers

August 7th 2018

Susanna Ulahannan, MD, highlights trials from the 2018 ASCO Annual Meeting across gastrointestinal malignancies and future therapeutic approaches across the landscape.

Dr. Ulahannan on the PRODIGE 35 Trial in Pancreatic Cancer

August 3rd 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.

Dr. Conroy on the Findings With Adjuvant mFOLFIRINOX in Pancreatic Cancer

August 2nd 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the findings with an adjuvant a modified FOLFIRINOX regimen in patients with nonmetastatic pancreatic ductal adenocarcinoma.

Dr. Choti on the Role of Surgery in Rectal Cancer

August 2nd 2018

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of surgery in the treatment of patients with rectal cancer.

Dr. Ulahannan on Immunotherapy in Hepatocellular Carcinoma

July 31st 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses immunotherapy in hepatocellular carcinoma (HCC).

Dr. Shah Discusses Challenges With Immunotherapy in Esophageal Cancer

July 31st 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses challenges with immunotherapy in esophageal cancer.

Perspectives on the Future Treatment of HCC

July 30th 2018

Anti-VEGF Therapy in Metastatic HCC

July 30th 2018

Multitargeted TKI Therapy in Metastatic HCC

July 30th 2018

Checkpoint Inhibitors Versus TKI Therapy in HCC

July 30th 2018

Immunotherapy in Second-Line Metastatic HCC

July 30th 2018

Appropriateness for Regorafenib in Metastatic HCC

July 30th 2018

Practical Considerations for Using Lenvatinib in HCC

July 30th 2018